Journal of Clinical Endocrinology & Metabolism, Vol 81, 3487-3491, Copyright © 1996 by Endocrine Society

ARTICLES

Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism

CY Guo, WE Thomas, AW al-Dehaimi, AM Assiri and R Eastell
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, United Kingdom.

The aims of this study were to determine 1) whether primary hyperparathyroidism (PHPT) is associated with accelerated bone loss in postmenopausal women, 2) whether bone mineral density (BMD) and bone turnover change to a similar extent with surgery and hormone replacement therapy (HRT) in these patients, and 3) whether biochemical markers of bone turnover measured at baseline can be used to predict the change in BMD in these patients after different therapies. We studied 33 postmenopausal women with PHPT; their ages at the time of study ranged from 48-80 yr (mean +/- SD, 63 +/- 10). Total body (TB), lumbar spine (LS), and femoral neck (FN) BMD and biochemical markers of bone turnover were measured at baseline and 10-30 months (19 +/- 5) after parathyroid surgery, HRT, or no treatment. BMD was measured in 33 age-matched healthy controls at baseline and at a mean of 24 months. Baseline biochemical markers of bone turnover were measured in controls. In PHPT at baseline, the mean z-score of BMD was -1.25 at TB (95% confidence interval, -1.64 to -0.86), -0.95 at LS (-1.37 to - 0.53), and -1.30 at FN (-1.65 to -0.95), whereas the mean z score was 0.45 for serum carboxy-terminal propeptide of human type I procollagen (0.02-0.89), 1.05 for bone alkaline phosphatase (0.38-1.71), 2.38 for 24-h urinary excretion of cross-linked N-terminal telopeptide of type I collagen (NTx; 1.63-3.13), and 2.36 for 24-h urinary excretion of galactosyl hydroxylysine (1.97-2.74). After surgery and HRT, BMD increased and bone turnover decreased during the follow-up. In the untreated group, BMD decreased at TB and FN, and levels of bone alkaline phosphatase, NTx/creatinine, and galactosyl hydroxylysine/creatinine increased. When the rate of change in BMD (percentage per yr) was compared with that in the control group, bone gain was significant at all three skeletal sites after surgery and HRT, and bone loss was significant at TB and FN, but not at LS, in the untreated group. There was a weak, but significant, correlation between baseline urinary NTx and the change in femoral neck BMD in the untreated group (r = -0.36; P = 0.05). We conclude that untreated postmenopausal women with PHPT have low BMD resulting from accelerated bone loss at the TB and FN. Surgery and HRT both restore BMD and bone turnover toward normal in postmenopausal women with PHPT. A single measurement of bone turnover is insufficient to predict BMD changes in individual patients with PHPT.

This article has been cited by other articles:

				A. Khan, A. Grey, and D. Shoback Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 373 - 381. [Abstract] [Full Text] [PDF]

				F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]

				G. El-Hajj Fuleihan Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms? J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3302 - 3304. [Full Text] [PDF]

				A. Grey, J. Lucas, A. Horne, G. Gamble, J. S. Davidson, and I. R. Reid Vitamin D Repletion in Patients with Primary Hyperparathyroidism and Coexistent Vitamin D Insufficiency J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2122 - 2126. [Abstract] [Full Text] [PDF]

				D. S. Rao, E. R. Phillips, G. W. Divine, and G. B. Talpos Randomized Controlled Clinical Trial of Surgery Versus No Surgery in Patients with Mild Asymptomatic Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5415 - 5422. [Abstract] [Full Text] [PDF]

				J. P. Bilezikian and S. J. Silverberg Asymptomatic Primary Hyperparathyroidism N. Engl. J. Med., April 22, 2004; 350(17): 1746 - 1751. [Full Text] [PDF]

				T. Bellido, A. A. Ali, L. I. Plotkin, Q. Fu, I. Gubrij, P. K. Roberson, R. S. Weinstein, C. A. O'Brien, S. C. Manolagas, and R. L. Jilka Proteasomal Degradation of Runx2 Shortens Parathyroid Hormone-induced Anti-apoptotic Signaling in Osteoblasts: A PUTATIVE EXPLANATION FOR WHY INTERMITTENT ADMINISTRATION IS NEEDED FOR BONE ANABOLISM J. Biol. Chem., December 12, 2003; 278(50): 50259 - 50272. [Abstract] [Full Text] [PDF]

				D. M. Shoback, J. P. Bilezikian, S. A. Turner, L. C. McCary, M. D. Guo, and M. Peacock The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5644 - 5649. [Abstract] [Full Text] [PDF]

				I. A. Nakchbandi, M. A. Mitnick, R. Lang, C. Gundberg, B. Kinder, and K. Insogna Circulating Levels of Interleukin-6 Soluble Receptor Predict Rates of Bone Loss in Patients with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4946 - 4951. [Abstract] [Full Text] [PDF]

				C. R. Parker, P. J. Blackwell, K. J. Fairbairn, and D. J. Hosking Alendronate in the Treatment of Primary Hyperparathyroid-Related Osteoporosis: A 2-Year Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4482 - 4489. [Abstract] [Full Text] [PDF]

				B. J. Orr-Walker, M. C. Evans, J. M. Clearwater, A. Horne, A. B. Grey, and I. R. Reid Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism: Four-Year Follow-up and Comparison With Healthy Postmenopausal Women Arch Intern Med, July 24, 2000; 160(14): 2161 - 2166. [Abstract] [Full Text] [PDF]

				A. Khan and J. Bilezikian Primary hyperparathyroidism: pathophysiology and impact on bone Can. Med. Assoc. J., July 1, 2000; 163(2): 184 - 187. [Abstract] [Full Text] [PDF]

				J. A. Eisman Genetics of Osteoporosis Endocr. Rev., December 1, 1999; 20(6): 788 - 804. [Abstract] [Full Text]

				J. R. Center, T. V. Nguyen, P. N. Sambrook, and J. A. Eisman Hormonal and Biochemical Parameters in the Determination of Osteoporosis in Elderly Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3626 - 3635. [Abstract] [Full Text] [PDF]

				A. Grey, M.-A. Mitnick, U. Masiukiewicz, B.-H. Sun, S. Rudikoff, R. L. Jilka, S. C. Manolagas, and K. Insogna A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo Endocrinology, October 1, 1999; 140(10): 4683 - 4690. [Abstract] [Full Text]

				H. G. Bone Who Needs Parathyroid Surgery? The Case for Parathyroidectomy in Nonclassical Primary Hyperparathyroidismb J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2278 - 2282. [Full Text]

				J. S. Finkelstein and A. L. Arnold Increases in Bone Mineral Density after Discontinuation of Daily Human Parathyroid Hormone and Gonadotropin-Releasing Hormone Analog Administration in Women with Endometriosis J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1214 - 1219. [Abstract] [Full Text]

				R. Eastell Treatment of Postmenopausal Osteoporosis N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746. [Full Text] [PDF]